FH phenotype: monogenic, polygenic and other causes by Mariano, C. et al.
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/cge.13697 
 
TITLE: THE FH PHENOTYPE: MONOGENIC FAMILIAL HYPERCHOLESTEROLAEMIA, POLYGENIC 
HYPERCHOLESTEROLAEMIA AND OTHER CAUSES 
 
SHORT TITLE: FH PHENOTYPE: MONOGENIC, POLYGENIC AND OTHER CAUSES 
 
AUTHORS 
Mariano C, PhD1,2; Alves AC; PhD1,2; Medeiros A, MSc1,2; Chora JR, MSc1,2; Antunes M, 
PhD3,4; Futema M, PhD5; Humphries SE, PhD6; Bourbon M, PhD1,2. 
 
AFFILIATIONS 
1Cardiovascular Research Group, Research and Development Unit, Department of Health 
Promotion and Chronic Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, 
Portugal; 
2University of Lisbon, Faculty of Sciences, BioISI – Biosystems & Integrative Sciences 
Institute, Lisbon, Portugal; 
3Department of Statistics and Operations Research, Faculty of Sciences, University of 
Lisbon, Lisbon, Portugal; 
4Centre of Statistics and its Applications – CEAUL, Faculty of Sciences, University of 
Lisbon, Lisbon, Portugal; 
5Centre for Heart Muscle Disease, Institute of Cardiovascular Sciences, University College 
London, London, United Kingdom. 
This article is protected by copyright. All rights reserved.
  
6Centre for Cardiovascular Genetics, Institute of Cardiovascular Sciences, University 
College London, London, United Kingdom. 
 
 
CORRESPONDING AUTHOR 
Mafalda Bourbon  
Instituto Nacional de Saúde Doutor Ricardo Jorge 
Av. Padre Cruz, 1649-016 Lisboa, Portugal 
Tel.: (+351) 217 519 200 | (+351) 217 508 126 
E-Mail: mafalda.bourbon@insa.min-saude.pt 
 
This article is protected by copyright. All rights reserved.
  
 
ACKNOWLEDGEMENTS 
The authors would like to thank all patients and clinicians for participating in the 
Portuguese Familial Hypercholesterolaemia Study and to all participants of the e_COR 
Study. The authors gratefully acknowledge Ana Raimundo (MSc) for performing the Lp(a) 
biochemical determinations, and all technicians of the Unidade de Diagnóstico e Referência 
(DPSPDNT−INSA) for performing the remaining lipid profile parameters, especially Suza 
Almeida and Marta Alvim.  Cibelle Mariano was supported by a PhD student grant 
[SFRH/BD/52494/2014]. Marta Futema is supported by the Fondation Leducq Transatlantic 
Networks of Excellence Program grant (no 14 CVD03). The work of Marilia Antunes is 
partially funded by UID/MAT/000016/2019. SEH acknowledges funding from the British 
Heart Foundation grant (BHF PG08/008) and from the NIHR UCLH BRC. MB 
acknowledges funding from Science and Technology Foundation (PIC/IC/83020/2007) 
(PIC/IC/83333/2007) for the e_COR and Portuguese FH Study and from Portuguese 
Cardiology Society for the Portuguese FH Study. 
 
Conflict of Interest Statement 
Authors declares no conflict of interest in relation to this manuscript. 
Data Availability Statement 
Authors declares absence of shared data. 
 
This article is protected by copyright. All rights reserved.
  
ABSTRACT  
Background: Familial Hypercholesterolaemia (FH) is a monogenic disorder 
characterised by high LDL-C concentrations and increased cardiovascular risk. However, in 
clinically defined FH cohorts worldwide, an FH-causing variant is only found in 40-50% of 
the cases. The aim of this work was to characterise the genetic cause of the FH phenotype in 
Portuguese clinical FH patients.  
Methods and Results: Between 1999 and 2017, 731 index patients (311 children and 
420 adults) who met the Simon Broome diagnostic criteria had been referred to our 
laboratory. LDLR, APOB, PCSK9, APOE, LIPA, LDLRAP1, ABCG5/8 genes were analysed 
by PCR amplification and Sanger sequencing. The 6-SNP LDL-C genetic risk score (GRS) 
for polygenic hypercholesterolaemia was validated in the Portuguese population and cases 
with a GRS over the 25th percentile were considered to have a high likelihood of polygenic 
hypercholesterolaemia. An FH-causing mutation was found in 39% of patients (94% in 
LDLR, 5% APOB and 1% PCSK9), while at least 29% have polygenic 
hypercholesterolaemia and 1% have other lipid disorders.  
Conclusions: A genetic cause for the FH phenotype was found in 503 patients (69%). 
All known causes of the FH phenotype should be investigated in FH cohorts to ensure 
accurate diagnosis and appropriate management. 
 
Keywords: Familial hypercholesterolaemia; monogenic dyslipidaemia; polygenic 
hypercholesterolaemia; genetic risk score; phenocopies. 
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INTRODUCTION 
Familial Hypercholesterolaemia (FH) is an autosomal dominant condition characterised 
by substantially increased plasma concentrations of low-density lipoprotein cholesterol 
(LDL-C) from birth, leading to premature atherosclerosis1. FH is one of the most common 
inherited disorders associated with premature coronary heart disease (pCHD), with a 
frequency around 1:250 in most populations2.  
The genetic causes of FH are pathogenic variants mainly in the LDL receptor gene 
(LDLR)1 or apolipoprotein B gene (APOB)3–5, and gain-of-function mutations in the 
proprotein convertase subtilisin/kesin type 9 gene (PCSK9)6. However, an increasing 
number of FH phenocopies are being identified and a few individuals with a clinical 
diagnosis of FH have been found to have rare variants in other genes, such as apolipoprotein 
E (APOE)7, ATP-binding cassette sub-family G member 5 or 8 (ABCG5/8)8 or lysosomal 
acid lipase (LIPA)9. Recently, studies have reported that a significant proportion of 
clinically-diagnosed FH patients where a disease-causing mutation was not found are likely 
to have a polygenic cause for their hypercholesterolaemia, due to the inheritance of a greater-
than-average number of common LDL-C raising single nucleotide polymorphisms (SNPs) 
with a cumulative effect, leading to an increase in LDL-C above the recommended FH 
diagnostic criteria10,11. Even in patients with a disease-causing mutation, this polygenic 
contribution to the FH phenotype is also present, contributing to a variable phenotype in 
patients with the same FH-causing mutation11. While originally 12 SNPs were used to define 
the polygenic contribution, a reduced 6-SNPs score has been found to provide adequate 
information10–12.  
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In terms of cardiovascular risk assessment, it is of particular clinical value to distinguish 
between monogenic and polygenic dyslipidaemia, since for all LDL-C intervals the 
cardiovascular disease (CVD) risk has been demonstrated to be higher in FH patients with a 
causative mutation compared to patients with the same LDL-C concentrations13. This 
highlights the concept of length of time of LDL-C exposure, or LDL-C “burden”14. Because 
of this, monogenic FH patients warrant treatment with high intensity and effective lipid-
lowering therapy to decrease their CVD risk, while those with a polygenic or environmental 
dyslipidaemia have a lower CVD risk and can be managed, for example by encouraging 
lifestyle and dietary changes, and with the use of more moderate dosage of lipid-lowering 
therapies. 
In clinically-defined FH cohorts worldwide, an FH-causing variant is found in only 40-
50% of the cases, although the prevalence of genetically identified FH patients will vary due 
to differences in molecular diagnostic methodologies, and also to differences in the clinical 
criteria applied1,4,15–17. In the remaining 50% of the cases, the cause for the 
hypercholesterolaemia must be sought, in order to offer appropriate management and 
prognosis advice to implement appropriate interventions for CVD prevention. Here, we 
report the characterisation of the FH phenotype in the Portuguese FH Study cohort. We also 
validated the 6-SNP LDL-C genetic risk score (GRS)10,11 in the Portuguese population. 
 
2. MATERIALS AND METHODS 
The Portuguese FH Study is a research project coordinated by the National Institute of 
Health (INSA) supported mainly by external funds and free of charge for all patients and 
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health institutions. INSA Ethical Committee and the National Data Protection Commission 
previously approved the study protocol and database. Written informed consent was 
obtained from all participants before their inclusion in the study. 
 
2.1. Study population  
A total of 887 index patients were enrolled in the Portuguese FH Study from 1999 to 
2017, referred from different clinical specialties with a clinical suspicion of FH. In the 
present report, we only included 731 index patients (311 children and 420 adults) with a 
clinical diagnosis of FH according to the Simon Broome (SB) criteria, as previously 
described18, with a single adaptation - individuals aged 16-18 were included with the SB 
criteria for children due to the mild phenotype seen in FH patients within this age range. All 
adult index cases included in this study fulfilled SB criteria prior to inclusion, 410 possible 
FH and 10 definite FH. The Dutch Lipid Clinic Network Score (DLCNS) for FH was applied 
to 390 of the 420 adults from the Portuguese FH Study. For the remaining 30 it was not 
possible to estimate the DLCNS value, due to missing LDL-C values. A total of 382 adults 
fulfilled DLCNS of definite (>8) (n=82), probable (>6) (n=169) or possible (>3) (n=131) 
FH and 8 are unlikely FH (<3). Additionally, 1777 relatives (393 children and 1384 adults) 
were referred to the Portuguese FH Study cascade-screening program (with or without a 
clinical diagnosis of FH). 
 
2.2. Monogenic dyslipidaemia analysis 
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Genetic diagnosis was performed by the molecular analysis of LDLR (including the 
study of splice regions and large rearrangements), APOB (two fragments of exons 26 and 
29), and PCSK9 genes, as previously reported19. Selected patients (Supplementary Table 1), 
where a variant was not found in the previously studied genes, were further investigated for 
other monogenic causes of dyslipidaemia; this was performed by polymerase chain reaction 
and Sanger sequencing of the following genes: APOE, LIPA, LDLR adapter protein 1 
(LDLRAP1), ABCG5 and ABCG8. Sequences were analysed with Staden software20 and the 
references used for analysis were NM_000527 for LDLR, NM_000384 for APOB,  
NM_174936 for PCSK9, NM_000041 for APOE, NM_015627 for LDLRAP1, NM_022436 
for ABCG5, NM_022437 for ABCG8 and NM_000235 for LIPA. Complementary DNA 
numbering was considered according to the Human Genome Variation Society (HGVS) 
nomenclature21 with nucleotide c.1 being A of the ATG initiation codon p.1. For one case 
the molecular study of  the albumin gene (ALB) was performed, but in an external laboratory 
22. 
All variants were checked with Mutalyzer 2.0, as recommended by Human Genome 
Variation Society (HGVS). Variants were classified as pathogenic, likely pathogenic, variant 
of uncertain significance (VUS), likely benign or benign, according to the American College 
of Medical Genetics and Genomics (ACMG) guidelines23 following specific adaptations 
described in Chora et al.24 The variants reported in the present study were considered novel 
if they were not described before in public databases25,26 or in PUBMED, and novel for 
Portugal if they were found for the first time in Portugal, but have been previously reported 
in another country. In silico analysis was performed as described before27. 
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Since 2012, our laboratory has participated in an external quality assessment (EQA) 
programme managed by the European Molecular Genetics Quality Network (EMQN)  that 
provide accreditation on basis of the ISO 17043. 
 
2.3. Polygenic hypercholesterolaemia analysis 
A total of 1318 genomic DNA samples from the e_COR Study28  and 410 index cases 
from the Portuguese FH Study from which quality DNA was available (168 children and 
242 adults) were sent to aScidea Computational Biology Solutions Company (Barcelona, 
Spain) to be genotyped for a set of 6 SNPs, using the OpenArray™ technology (Life 
Technologies, Carlsbad, California, US). 
The LDL-C GRS was calculated using the 6 SNPs previously reported in the 
characterisation of polygenic hypercholesterolaemia, namely, cadherin EGF LAG seven-
pass G-type receptor 2 (CELSR2)/ sortilin 1 (SORT1) (rs629301), APOB (rs1367117), 
ABCG5/8 (rs4299376), LDLR (rs6511720) and APOE (rs7412 and rs429358) and respective 
effect sizes (weighted sum of beta-coefficients of the risk allele)11 (Supplementary Table 2).  
The e_COR Study population28 was used as reference group for the validation of the 
LDL-C GRS in the Portuguese population. LDL-C scores were distributed into quarters; 
individuals below the 25th percentile (P25th) were considered as having low polygenic score, 
between the P25th and the 75th percentile (P75th), intermediate polygenic score, and above 
the P75th, high polygenic score. The GRS cut-offs were applied to the Portuguese FH Study 
population accordingly. 
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2.4. Biochemical characterisation of lipids and lipoproteins 
For both cohorts, The Portuguese FH Study and e_COR study, the biochemical tests for 
Total Cholesterol (TC), direct LDL-C, high-density lipoprotein cholesterol (HDL-C), 
triglycerides (TG), Apolipoprotein A1 (apoA1), and Apolipoprotein B (apoB) were 
performed by enzymatic colorimetric and immunoturbidimetric methods. Serum levels of 
lipoprotein (a) [Lp(a)] were determined by an immunoturbidimetric method, as previously 
described27. 
 
2.5. Correction factors regarding lipid-lowering therapy 
Whenever untreated lipid values (TC, LDL-C and apoB) for individuals under statins 
medication were not available, these were estimated using correction factors. Therapy is 
expected to decrease the values of TC, LDL-C 13,29,30 and apoB31 by 20%, 30% and 23.7%, 
respectively. Untreated TG, HDL-C and apoA1 values were not estimated, since the effects 
of lipid-lowering therapy with statins are not significant on these traits32,33. 
 
2.6. General statistical analysis 
Statistical analyses were performed using R (version 3.1.2) software. For comparison of 
mean concentrations of lipids, lipoproteins and LDL-C GRS values between independent 
groups, the non-parametric Two-sample Wilcoxon or Kruskal-Wallis tests were applied for 
two or more independent samples, respectively. When the trait distributions did not fail the 
assumptions of normality (Shapiro-Wilk or Kolmogorov-Smirnov tests) and homogeneity 
of variance (Bartlett test), the parametric ANOVA or Student t tests were applied for two or 
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more independent samples. For comparison of proportions, the 95% confidence intervals 
(CI) were used and when the two CI did not overlap, it was considered that there was 
evidence to conclude that the proportions are statistically different. In the remaining cases 
(overlap of the two proportions confidence intervals), the two proportions were compared 
using chi-square or Fisher's tests. The multiple of median (MoM) was calculated for the 
LDL-C, TG and apoB measured values to analyse how far those values deviated from the 
median of a reference population. For phenotype versus genotype analysis the biochemical 
values at referral were used (corrected as described when necessary). 
 
3. RESULTS 
3.1. Demographic and clinical data 
Demographic and clinical data on cardiovascular disease risk factors of all index cases 
are shown in Supplementary Table 3, including the non-treated lipid profile (when 
available), and the complete fasting lipid profile performed at our Institute for all individuals 
at referral to the Portuguese FH Study. Mean age (years) at referral was 9.94 (± 3.69) for 
children and 45.67 (± 13.32) for adults. Approximately 20% of the children were under 
pharmacological treatment at referral compared with 75% of the adults. The majority (>95%) 
of the patients are of Portuguese nationality distributed over all regions of Portugal. 
 
3.2. Monogenic dyslipidaemia 
A total of 731 index cases were analysed for LDLR, APOB and PCSK9 genes. In 282 
(39%) patients (128 children and 154 adults) a pathogenic or likely pathogenic variant was 
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found, including 3 true homozygous and 6 compound heterozygous (2 children and 7 adults); 
these will be referred as FH mutation positive (FH/M+) subjects (Supplementary Table 4). 
In 399 (54%) patients (159 children and 239 adults) no potential pathogenic variants were 
found; these will be referred as FH mutation negative (FH/M-) subjects. Additionally, 18 
children and 26 adults were found to have a VUS. Based on phenotype (Supplementary 
Table 1), selected FH/M- patients were analysed for other possible causes of monogenic 
dyslipidaemia; 6 cases were found to have another monogenic dyslipidaemia. 
 
3.2.1. Familial Hypercholesterolaemia 
In about 39% of all index patients (n=282/731), at least one pathogenic or likely 
pathogenic variant was identified in the LDLR, APOB or PCSK9 genes. In the paediatric 
index cohort (n=311), 41% individuals had genetically heterozygous FH (HeFH) (n=126) or 
homozygous FH (HoFH) (n=2). In the adult index cohort (n=420), 37% individuals had 
genetically HeFH (n=147) or HoFH (n=7). A VUS in the LDLR and APOB genes were found 
in 6% of children (n=18) and 6% of adults (n=26), corresponding to 35 individuals with a 
VUS in the LDLR and 9 individuals in the APOB gene. The cascade-screening programme 
led to the additional identification of 116 HeFH children, 314 HeFH adults and 1 HoFH 
adult. Additionally, 38 relatives (7 children and 31 adults), had a VUS. 
Since our last report in 201527, 8 LDLR novel variants have been identified in our cohort 
(5 never described before and 3 described in other countries, but novel for Portugal). All 
variants have already been submitted to ClinVar (Supplementary Table 4 and 5). From these, 
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only 3 variants are considered pathogenic or likely pathogenic: 
c.2214del/p.(Gln739Serfs*26), c.941-2A>C, and c.1897C>T/p.(Arg633Cys). 
For both children and adults, the demographic, clinical and biochemical profile of the 
FH/M+ group were compared to the FH/M- group, and are presented in Table 1. Patients 
with a VUS, homozygous patients and patients with other monogenic causes (discussed in 
the next section) were not included in this analysis. Although all FH/M- patients have a 
clinical phenotype compatible with a diagnosis of FH, they have lower mean levels of TC, 
LDL-C, non-HDL-C, apoB, and apoB/apoA1 ratio, and higher levels of HDL-C and TG, 
than the FH/M+ group. These differences are more evident in the paediatric cohort. Also, 
the percentage of adult FH/M- patients with hypertriglyceridaemia (defined as TG ≥200 
mg/dL) was higher than in the FH/M+ patients (20% (n=47/235) versus 8.33% (n=12/44), 
P=0.002). The opposite was observed for apoB, a higher number of FH/M+ patients (87.85% 
(n=123/140)) had apoB ≥120 mg/dL compared to FH/M- (64.94% (n=150/231), P<0.001). 
No significant differences were observed for Lp(a) values. In adults, there are no statistically 
significant differences for CVD, premature CVD or family history of CVD between FH/M+ 
and FH/M- individuals (Table 1).   
The mean lipid concentrations of the FH/M+ index and FH/M+ relatives presented 
significant differences: TC, LDL-C, apoB, non-HDL-C and apoB/apoA1 ratio were 
statistically higher in index cases, except in the paediatric cohort where the apoB values and 
apoB/apoA1 ratio did not differ between these two groups (Supplementary Table 6). 
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3.2.2. Other monogenic disorders 
In selected FH/M- patients (Supplementary Table 1), disease-causing variants in the 
APOE, LIPA, ABCG8 and ALB genes were found in 6 index patients (five children and one 
adult). Three children had lysosomal acid lipase deficiency (LALD) (due to homozygosity 
for the c.894G>A variant in LIPA), as previously published9, one had sitosterolemia (due to 
homozygosity for the c.1974C>G variant in ABCG8) and one had congenital analbuminemia 
(due to heterozygosity for the  c.1289+1G>A variant in ALB)22. An additional child had an 
heterozygous stop variant in APOE (c.683G>A) that has been associated in the homozygote 
state with dysbetalipoproteinemia34, so it was not considered as causative (Supplementary 
table 5). In the adult cohort, one individual was heterozygous for a variant in APOE 
(c.487C>T), previously associated with autosomal dominant hypercholesterolaemia35 
(Supplementary table 5). Additionally, one relative (child) was also found to have LALD 
and one (adult) sitosterolaemia9. 
 
3.2.3. Overall monogenic dyslipidaemia 
A molecular cause of monogenic dyslipidaemia was found in 39% (n=288/731) of all 
index cases with an FH phenotype. In the monogenic dyslipidaemia paediatric group, 91% 
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had an FH-causing variant in LDLR, 5% in APOB, 1% in PCSK9, 2% in LIPA, 1% in ALB 
and 1% in ABCG8. In the adult group, 93% had an FH-causing variant in LDLR, 5% in 
APOB, 1% in PCSK9 and 1% in APOE. Altogether, other monogenic causes represent 2% 
(6/288) of monogenic hypercholesterolaemia index cases in our cohort, with a non-
significantly (p=0.32) higher proportion in children (4%, 5/133) (Figure 1). 
 
 
3.3. Polygenic hypercholesterolaemia 
The mean value of the LDL-C GRS calculated in the e_COR population was 0.62 
(+0.22) with a mean LDL-C of 135.8 mg/dL (+46.34) [3.51 mmol/L (+ 1.20)] 
(supplementary Figure 1). The distribution of the LDL-C concentration values by GRS 
percentiles in e_COR is shown in supplementary Table 7. Individuals above the P75th of 
LDL-C GRS (0.76) had significantly higher LDL-C (P<<0.001) than individuals below the 
P25th (LDL-C GRS 0.51) (supplementary Figure 2). When comparing the mean GRS values 
between Portuguese e_COR and UK Whitehall II (WHII) controls10, no significant 
differences were found (0.62 (SD 0.22) CI=[0.61-0.63] versus 0.63 (SD 0.22) CI=[0.62-
0.64], respectively). 
 
Of all 731 clinical FH index cases, the LDL-C GRS was calculated for 410 individuals 
from whom DNA was available, 168 children and 242 adults. Compared with e_COR 
controls, both FH/M- (0.73±0.18) and FH/M+ (0.69±0.19) patients had higher mean LDL-
C GRS (P<<0.001) (Supplementary Figures 2-3). In this small sample, no statistically 
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significant differences were found comparing FH/M- and FH/M+ patients. In the paediatric 
cohort, the mean value was 0.73 (+ 0.17) for FH/M- (n=92) and 0.71 (+ 0.19) for FH/M+ 
(n=76), and in the adult cohort was 0.72 (+ 0.19) for FH/M- (n= 151) and 0.68 (+ 0.20) for 
FH/M+ (n=91). 
 
The distribution of the GRS in the paediatric FH/M- was: 13% (n=12) below the P25th, 
21.7% (n=20) between P25th and P50th; 22.8% (n=21) between P50th and P75th and 42.4% 
(n=39) above the P75th (Figure 2). In the adult FH/M- cohort the distribution of the GRS 
was: 10.6% (n=16) below the P25th, 19.9% (n=30) between P25th and P50th; 29.1% (n=44) 
between P50th and P75th and 40.4% (n=61) above the P75th (Figure 2).  
 
3.4. Overall proportion with an identified genetic cause for the FH phenotype 
Overall, including both patients with homozygous (n=9) and heterozygous FH (n=273) we 
have identified a monogenic cause for the FH phenotype in 39% (n=282/731) of patients. 
We also found 6 patients with other monogenic disorders: 3 with lysosomal acid lipase 
deficiency (LALD), 1 with sitosterolaemia, 1 with albuminuria and 1 with 
dysbetalipoproteinemia, representing 0.8% (n=6/731) of all patients. All adults that were 
tested for polygenic dyslipidaemia fulfilled both the DLCN and SB clinical criteria, so 
genetic diagnosis rate was the same. 
 
For the FH/M- patients for whom the LDL-C GRS was determined (92 children and 151 
adults), 39 children and 61 adults had a polygenic score above P75th, which represents 14% 
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of overall patients in the study (n=731), while an additional 15.7% of overall (41 children 
and 74 adults) had an intermediate polygenic score (Figure 3 and supplementary Figure 4). 
Of the remaining FH/M- patients, 28 (12 children and 16 adults) presented a score below 
P25th and are therefore most likely to have an unknown or unidentified cause of monogenic 
dyslipidaemia (Figure 3 and supplementary Figure 4).  By including LDL-C GRS analysis 
and sequencing of genes involved in other monogenic dyslipidemias we increased the 
identification rate from 41% to 68.5% in the paediatric cohort and from 37% to 69% in the 
adult cohort (Figure 3). 
 
4. DISCUSSION 
Portuguese FH Study 
For the index cases referred to the Portuguese FH Study, in 69% we have identified the 
cause of hypercholesterolaemia: 39.4% with monogenic hypercholesterolaemia (38.6% have 
FH and 0.8% other monogenic causes), 16% with intermediate polygenic 
hypercholesterolaemia score and 14% with high polygenic hypercholesterolaemia score. The 
variants of unknown significance will need further characterization to be confirm of refute 
their causality of disease, if all VUS are indeed pathogenic (found in 6%), the total number 
of positives cases with a monogenic disorder will increase to 45% and the total identification 
rate to 75%. Cascade screening was performed for relatives of FH cases and 430 relatives 
were identified with heterozygous FH, one was a compound heterozygous, and 38 relatives 
with VUS. For individuals with an intermediate or high polygenic score, cascade screening 
was not performed. Futema and colleagues36 described that a cascade screening for 
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individuals with an intermediate or high polygenic score is less cost effective, since, as 
compared to the 50% of mutation carriers seen in first degree relatives of monogenic 
families, only ~30% of relatives are likely to have LDL-C elevated above the diagnostic 
threshold. 
From 2014 to 2017, a total of 10 novel variants were identified in our cohort, 5 never 
described before in association with FH, showing that the cause of FH in Portugal is 
heterogeneous, with more than 140 different variants (mainly in the LDLR), and that new 
variants are still being found, as reported for other populations.  
 
In the Portuguese FH Study only if a variant is classified as pathogenic or likely 
pathogenic (ACMG), or if the variant is designated as a VUS, only after functional in vitro 
assessment with proof of affected function, the clinician is informed that the variant found 
confirms or is consistent with the clinical diagnosis. Due to the establishment of functional 
studies in our lab37,38, the majority of the mutations found in the Portuguese population 
(120/142) have a classification of pathogenic or likely pathogenic following ACMG 
guidelines24, and this results  in more than 80% of our cohort of FH/M+ patients having a 
molecularly confirmed  FH diagnosis. The implementation of functional studies as an 
adjunct to work in diagnostic laboratories improves the genetic diagnosis of FH, and should 
be encouraged worldwide. 
The presence of xanthomas following SB criteria attributes a definite FH diagnosis. 
Interestingly we have observed a low rate of xanthomas even in adults (7.5%) when 
compared to other European populations, including our neighbours the Spanish population 
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(19%). In our clinical FH children, so far no xanthomas have been identified, not even in the 
homozygotes. The short exposure time may be a justification, but considering that in adults 
the percentage is low, we believe that the Mediterranean diet may be acting as a protective 
factor against the development of xanthomas.  
 
Correctly identifying the cause of dyslipidaemia 
In studies from many different countries, in 50-60% of individuals with a clinical 
diagnosis of FH the molecular cause of their hypercholesterolaemia could not be identified1. 
Talmud et al raised the possibility that the majority of those where no mutation could be 
found in LDLR/APOB/PCSK9 were likely to have a polygenic aetiology, while Wang and 
colleagues39 suggested that in some cases, the FH phenotype could be due to variants in other 
genes yet to be described, other genes of lipid metabolism, interactions between known 
genes, variants inaccessible by the currently sequencing techniques, epigenetics or even 
environmental factors per se. Taking this into consideration, our group started to analyse 
other monogenic and polygenic causes of hypercholesterolaemia in patients with a clinical 
diagnosis of FH, but without an identified FH causing variant. This has led to an increase in 
the genetic diagnosis of dyslipidaemia in additional 30% of patients (from 38.6% to 68.8%).   
In the great majority of the index patients, the cause of the dyslipidaemia is explained 
by a functional LDLR variant (36%), 1.9% by a functional APOB variant and 0.4% by a 
functional PCSK9 variant. Additionally, in at least 29% of patients, a polygenic dyslipidemia 
is the probable cause and in 0.8% other monogenic disorders are the cause of the phenotype. 
These other causes are more prevalent in children, representing 1.6% of all cases. It is worth 
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noting that other causes are more prevalent than PCSK9 mutations (0.4%), reinforcing the 
need to study these FH phenocopy genes, so as to allow a more complete diagnosis and 
management. There are considerable differences in the treatment of these different molecular 
causes of the FH phenotype. 
Higher Lp(a) has also been described as a possible FH phenocopy, but in our sample, 
although the FH/M+ patients had higher median concentrations of Lp(a) than the FH/M- 
group, the differences were not statistically significant, so Lp(a) concentrations do not seem 
to contribute to the clinical phenotype of FH in our sample. However, it is possible that 
increasing the number of individuals with measures of Lp(a) concentrations may identify a 
group of patients where this trait is the cause of the clinical diagnosis of FH. 
Our results are also consistent with previous studies showing that FH negative patients 
have higher mean LDL-C GRS than individuals from the general population, meaning that 
their LDL-C plasma levels is most likely to be due to the influence of a combination of 
several LDL-C variants, each with modest effect. In this paper we have used the 6-SNP GRS 
and used a cut-off of greater than the 25th percentile as being highly likely for an individual 
to have a polygenic cause of their FH phenotype. This is based on statistical modelling that 
was carried out previously10,11and as has recently been described in more detail36. The 
analysis shows that the probability of a polygenic cause for elevated LDL-C in FH/M-
individuals with a score above the 25th percentile is >98% for a range of frequencies of an 
unknown monogenic cause (modelled as between 0.001-0.01). This fully justifies that, 
except for those with a SNP score in the lowest 25%, all other FH/M subjects have a high 
probability of a polygenic case explaining their FH phenotype.  
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A limitation of our study is that not all FH/M- patients were genotyped for the 
polygenic score (only 243/398 were analysed) due to DNA constraints, so the proportion of 
patients with polygenic hypercholesterolaemia could only be estimated. For some 
comparison analysis in the polygenic dyslipidaemia, the small sample size could imply bias. 
Although it is considered as a limitation of our study, our results are in line with the 
previously reported10,11. Also, especially for adults, the untreated TC, LDL-C and apoB 
values had to be estimated for those undergoing lipid-lowering therapy and this might 
imperfectly estimate the untreated values due to the heterogeneity in drug response, dosing 
and variability in baseline lipid values. However, the 30% reduction in LDL-C and 20% in 
TC was implemented in previous studies13,29,31.  
Interestingly, a similar proportion of patients above the P75th was found in the FH/M+ 
and the FH/M- group, a finding which was reported previously10. This suggests that the FH 
phenotype in FH/M+ patients could be modulated by the modest effect of these LDL-C 
raising variants, at least at some level, however we did not find a statistical difference in 
LDL-C values, partly because of the selection criteria and partly due to the small sample 
size.  
Unknown dyslipidaemia in the FH mutation negative patients 
Twenty eight FH/M- patients presented a low LDL-C GRS (below the P25th) and are 
likely to have other unknown or unidentified cause of monogenic dyslipidaemia. It is likely 
that in a small fraction of these patients a new gene causing FH is yet to be discovered, 
although other possibilities should be considered, such as interactions between known genes 
or epigenetics. However, and since the mean triglyceride levels are statistically higher in 
This article is protected by copyright. All rights reserved.
 
 
FH/M- patients, in these cases environmental factors per se could be the cause of the 
phenotype39, or these patients could have another dyslipidaemia related to triglycerides 
metabolism and not FH.  
Importance of distinguishing the different causes of dyslipidaemia 
Monogenic dyslipidaemias present a severe phenotype and are associated with an 
elevated CVD risk per se, like FH, while mild to severe dyslipidaemias are mostly due to 
polygenic hypercholesterolaemia, as a result of various genetic alterations that may interact, 
as well as being modulated by non-genetic factors as life style40 . The distinction between 
these two types of dyslipidaemia is important for patient cardiovascular risk assessment and 
therapeutic management. It has been shown that FH patients with a pathogenic variant have 
16 times greater cardiovascular risk compared to another individual with the same LDL 
value13, but this risk can be reduced if FH patients are identified early in life and treated 
accordingly. This shows the importance of correctly identifying the cause of dyslipidaemia 
in early age and of addressing other cardiovascular risk factors in childhood, to reduce CVD 
rates later in adulthood.  
 
CONCLUSIONS 
With the strategy presented, it was possible to identify the cause of the 
hypercholesterolaemia in 503 patients representing 69% of our cohort. This work shows that 
the FH phenotype can be caused by several different genotypes, especially in paediatric 
cohorts. The correct identification of the cause of the dyslipidaemia is important for patient 
management and implementation of the best therapeutic measures for the best patient 
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prognosis. Our data support the view that the genetic diagnosis of clinical FH patients would 
benefit from the inclusion of all the genes studied in this work and to include the LDL-C 
GRS in a next-generation target panel. Such a panel is already implemented in our 
laboratory, and will not have a significant increase in cost. This has also been already 
recommended in the last consensus paper authored by international FH experts41. 
Investigation of other genes causing the FH phenotype in established FH cohorts should be 
encouraged. 
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Legends of Figures 
Figure 1 – Percentage of the different monogenic causes of dyslipidaemia in children (A) and 
adults (B). (A) 91% of children had an FH-causing variant in LDLR, 5% in APOB, 1% in 
PCSK9, and 4% of all children had other monogenic causes. (B) 93% of adults had an FH-
causing variant in LDLR, 5% in APOB, 1% in PCSK9 and 1% of adults had other monogenic 
causes. 
 
Figure 2 -Distribution of general population (e_COR) and FH/M- adults and children by 
GRS. 
 
Figure 3 – Number of index cases, children and adults, referred to the Portuguese Familial 
Hypercholesterolaemia (FH) Study with Simon Broome FH clinical criteria divided by the 
different causes of the FH phenotype and percentages of identification rate by group and total. 
FH refers to patients with pathogenic or likely pathogenic variants in either LDLR, APOB or 
PCSK9, intermediate GRS (genetic risk score) to patients with a LDL-C GRS between P25th 
and P75th, high GRS to patients with GRS above P75th. Other monogenic causes are: in children, 
3 with lysosomal acid lipase deficiency (mutation in the LIPA gene), 1 with sitosterolaemia 
(mutation in the ABCG8 gene) and 1 with analbuminemia (mutation in ALB gene); in adults, 1 
with an autosomal dominant hypercholesterolaemia (mutation in the APOE gene). 
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Table 1– Clinical, demographic and biochemical profile of children and adult index cases in the 
Portuguese Familial Hypercholesterolaemia Study with (FH/M+) and without (FH/M-) an identified 
mutation:  
 Paediatric cohort (n=285)
a  Adult cohort (n=386)
a
 
Clinical and demographic profile FH/M- FH/M+ 
P 
valuec 
 
FH/M- FH/M+ P value
c 
n (%) 159 (51.1) 126 (40.5) ND  239 (56.9) 147 (35.0) ND 
Age, years (SD)* 9.77 (3.5) 10.0 (3.9) NS  47.2 (11.9) 43.73 (14.9) 0.008 
Male gender, n (%) 63 (39.6) 63 (50.00) NS  118 (49.4) 57 (38.8) NS 
BMI, kg/m2 (SD)* 20.3 (4.3) 18.9 (3.5) 0.012  26.1 (4.2) 26.1 (4.9) NS  
Smoking, n (%) 0 1 (0.8) ND  56 (23.4) 21 (14.3) 0.025 
Alcohol consumption, n (%) 0 0 ND  86 (35.9) 40 (27.2) NS 
Hypertension, n (%) 3 (1.89) 0 ND  61 (25.5) 41 (27.9) NS 
Diabetes, n (%) 1 (0.63) 0 ND  9 (3.8) 5 (3.4) ND 
Personal history of CVD, n (%) 0 0 ND  51 (21.3) 31 (21.1) NS 
Personal history of pCVD, n (%) 0 0 ND  41 (17.2) 20 (13.6) NS 
Family history of pCVD, n (%) 26 (16.4) 24 (19.1) NS  80 (33.5) 43 (29.3) NS 
Pharmacological treatment (e.g. 
statins), n (%) 
18 (11.3) 36 (28.6) <0.001 
 
183 (76.6) 109 (74.2) NS 
On diet, n (%) 86 (54.1) 50 (39.7) 0.021  30 (12.6) 14 (9.5) NS 
Physically active, n (%) 119 (74.8) 86 (68.3) NS  81 (33.9) 52 (35.4) NS 
Tendon xanthoma, n (%) 0 0 ND  0 10 (6.8) ND 
Corneal arcus, n (%)  0 0 ND  1 (0.4) 13 (8.8) ND 
Other xanthomas, n (%) 0 1 (0.8) ND  13 (5.4) 16 (10.9) ND 
Lipid profile
b
        
Total cholesterol, mg/dL (IQR)† 239.2 (211-259) 273.4 (245-302) 
<<0.00
1 
 
285.0 (242-321) 
331.3 (284-
395) 
<<0.001 
LDL-C, mg/dL (IQR) † 156.9 (135-178) 
203.6 (5=179-
238) 
<<0.00
1 
 
201.7 (158-246) 
263.6 (207-
318) 
<<0.001 
HDL-C, mg/dL (IQR) † 57.2 (49-68) 50.9 (42-58) <0.001  55.0 (44-64) 51.0 (44-62) NS 
Triglycerides, mg/dL (IQR) † 84.5 (65-119) 65.0 (54 -88) <0.001  129.0 (100-178) 112.4 (83-148) <0.001 
ApoB, mg/dL IQR) † 99.5 (85-122) 129.5 (113-151) 
<<0.00
1 
 
136.8 (136-179) 
177.6 (141-
211) 
<<0.001 
ApoA1, mg/dL (IQR) † 150.0 (136-174) 135.0 (115-147) 
<<0.00
1 
 
155.7 (136-179) 
146.5 (127-
167) 
0.005 
Non-HDL-C, mg/dL (IQR) † 172.0 (153-194) 216.1 (192-253) 
<<0.00
1 
 
222.1 (182-270) 
274.9 (224-
328) 
<<0.001 
ApoB/ApoA1 ratio, mg/dL (IQR) † 0.7 (00.5-0.8) 1.0 (0.85-1.18) 
<<0.00
1 
 
0.9(0.68-1.17) 1.2 (0.9-1.6) <<0.001 
Lp(a), mg/dL (IQR) † 32.0 (10-80) 24.6 (10-44) 0.081  30.0 (9-72) 35.2 (9-92) NS 
FH, Familial Hypercholesterolaemia; FH/M-, FH mutation negative; FH/M+, FH FH/M+; BMI, body mass index; CVD, cardiovascular disease; pCVD, 
premature cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ApoB, apolipoprotein B; ApoA1, 
apolipoprotein A1; Lp(a), lipoprotein(a); SD, standard deviation; IQR, interquartile range; ND, Not determined; NS, Not statistically significant (P value 
><0.05) Age and BMI are expressed as mean (SD), while biochemical lipid values are expressed as median (IQR). 
a
Only heterozygous patients with pathogenic 
or likely-pathogenic variants were considered as FH/M+. Homozygous FH and patients with variants of uncertain significance (VUS) were excluded. 
b
Lipid 
profile determined in house. Correction factors were used to estimate untreated values for TC, LDL-C, and apoB, as described in the Material and Methods 
section of our study. 
c
Statistical significance (P value <0.05), in bold. 
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